Antihistamines: H1 Receptors, 2026 Urticaria Treatment and Drug Safety

Evidence-informed pharmacology review, updated 10 November 2026. For education; use current local guidance and individual clinical assessment.

Overview

Antihistamines are used principally for allergic rhinitis, urticaria, allergic conjunctivitis and selected symptomatic conditions. Most allergy medicines are H1-receptor inverse agonists, not simple competitive antagonists. H2-receptor blockers such as famotidine suppress gastric acid and are not interchangeable with H1 agents [1,2].

Classification and receptor mechanism

  • First-generation H1 agents: diphenhydramine, chlorpheniramine, promethazine and hydroxyzine readily cross the blood-brain barrier, causing sedation and antimuscarinic effects.
  • Second-generation H1 agents: cetirizine, levocetirizine, loratadine, desloratadine, fexofenadine, bilastine and others generally cause less CNS impairment, although cetirizine and levocetirizine can still sedate.
  • H2 agents: famotidine and cimetidine primarily reduce gastric acid.

The ‘third-generation’ designation is not a uniformly accepted separate pharmacological class. H1 receptors couple predominantly to Gq/11, triggering phospholipase C/IP3 pathways; inverse agonists stabilize the inactive receptor state [1].

Evidence-based urticaria care in 2026

The international 2026 urticaria guideline recommends standard-dose modern second-generation H1 antihistamines as first-line therapy. If chronic urticaria persists, clinician-supervised up-dosing of a single second-generation agent to a maximum of four times the licensed daily dose may be considered before additional treatments; this exceeds some product-label indications. The guideline favors omalizumab as an add-on for inadequately controlled disease, with further specialist options for refractory cases. Combining multiple different antihistamines is not preferred over appropriate up-dosing [2].

Allergic rhinitis and anaphylaxis

Oral or intranasal H1 antihistamines reduce sneezing, itching and rhinorrhea; intranasal corticosteroids generally control persistent or moderate–severe rhinitis more effectively. For anaphylaxis, intramuscular epinephrine is first-line; antihistamines may relieve skin symptoms only after emergency treatment and must never delay epinephrine [1].

Pharmacokinetics, safety and interactions

Loratadine undergoes CYP-mediated metabolism to desloratadine; fexofenadine has limited metabolism; cetirizine and levocetirizine require greater renal-function consideration. First-generation medicines cause impaired driving, delirium, urinary retention, dry mouth, falls and hazardous overdose, particularly in older people and children. Hydroxyzine and certain older agents can prolong QT. Avoid combining sedating agents with alcohol, opioids or other CNS depressants [1,2].

Clinical summary

Select non-sedating second-generation preparations for routine allergic disease where appropriate. Review kidney function, pregnancy/lactation status, age, driving demands and medication interactions. Do not assume that antihistamines prevent airway compromise in anaphylaxis [1,2].

References

  1. Brunton LL, Knollmann BC, editors. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th ed. McGraw Hill; 2023.
  2. Zuberbier T, Abdul Latiff AH, Abuzakouk M, et al. The international guideline for the definition, classification, diagnosis and management of urticaria. Allergy. 2026. doi:10.1111/all.70210. Available from: https://doi.org/10.1111/all.70210
Medical & AI Disclaimer

The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.

We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.

Leave a Reply

Your email address will not be published. Required fields are marked *